<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM13435</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-13435</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Анализ стратификации риска сахарного диабета 2 типа у лиц с клиническими признаками десинхроноза</article-title><trans-title-group xml:lang="en"><trans-title>Analysis of the risk stratification of type  2 diabetes mellitus in individuals with clinical signs of desynchronosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9885-8029</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нелаева</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nelaeva</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нелаева Юлия Валерьевна, д.м.н., заместитель директора Института общественного здоровья и цифровой медицины, доцент кафедры госпитальной терапии с курсом эндокринологии </p><p>Тюмень</p></bio><bio xml:lang="en"><p>Yulia V. Nelaeva, MD, PhD</p><p>Tyumen</p></bio><email xlink:type="simple">khasanova76@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0823-2538</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нелаева</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nelaeva</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нелаева Алсу Асатовна, д.м.н., профессор кафедры госпитальной терапии с курсом эндокринологии </p><p>Scopus Author ID: 726697</p><p>Тюмень</p></bio><bio xml:lang="en"><p>Alsu A. Nelaeva, MD, PhD, Professor</p><p>Tyumen</p></bio><email xlink:type="simple">alsu.nelayeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-3201-382X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ведерникова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Vedernikova</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ведерникова Софья Андреевна, аспирант кафедры госпитальной терапии с курсом эндокринологии </p><p>625023, г. Тюмень, ул. Одесская, д. 54</p></bio><bio xml:lang="en"><p>Sofya A. Vedernikova, MD</p><p>Tyumen</p></bio><email xlink:type="simple">sofiagnedina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Архипова</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Arkhipova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Архипова Марина Сергеевна</p><p>Тюмень</p></bio><bio xml:lang="en"><p>Marina S. Arkhipova, MD</p><p>Tyumen</p></bio><email xlink:type="simple">kartoshka-1990@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-0231-3616</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лихачева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Likhacheva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лихачева Елизавета Александровна </p><p>Тюмень</p></bio><bio xml:lang="en"><p>Elizaveta А. Likhacheva, MD</p><p>Tyumen</p></bio><email xlink:type="simple">elshbetta-86@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Тюменский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tyumen State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>26</day><month>07</month><year>2026</year></pub-date><volume>29</volume><issue>3</issue><fpage>237</fpage><lpage>244</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Нелаева Ю.В., Нелаева А.А., Ведерникова С.А., Архипова М.С., Лихачева Е.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Нелаева Ю.В., Нелаева А.А., Ведерникова С.А., Архипова М.С., Лихачева Е.А.</copyright-holder><copyright-holder xml:lang="en">Nelaeva Y.V., Nelaeva A.A., Vedernikova S.A., Arkhipova M.A., Likhacheva E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/13435">https://www.dia-endojournals.ru/jour/article/view/13435</self-uri><abstract><sec><title>ОБОСНОВАНИЕ</title><p>ОБОСНОВАНИЕ. В условиях устойчивого роста распространенности ожирения и связанных с ним кардиометаболических осложнений возрастает значимость выявления дополнительных факторов риска, среди которых особое место занимают нарушения сна и сокращение его продолжительности, способствующие формированию и прогрессированию метаболических нарушений.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Оценка выраженности нарушения цикла «сон-бодрствование» у пациентов с избыточной массой тела и ожирением I степени и разными категориями риска нарушений углеводного обмена по шкале FINDRISC.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. В исследование включены 1500 пациентов европеоидной расы обоего пола в возрасте 45–70 лет с ИМТ ≥25 кг/м². Проводилось анкетирование с использованием опросников FINDRISC (для расчета риска развития сахарного диабета), PSQI («Питтсбургский индекс качества сна за последний месяц») и ИТИ («Индекс тяжести инсомнии»).</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Ретроспективный анализ показал, что у 96,6% пациентов в возрасте 45–64 лет имелись избыточная масса тела или ожирение I степени. На втором этапе исследования из 782 пациентов с умеренным и высоким десятилетним риском развития СД2 по шкале FINDRISC у 696 (89,0%) зарегистрировано нарушение сна.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. У пациентов с избыточной массой тела и ожирением I степени с умеренным и высоким десятилетним риском СД2 по шкале FINDRISC, целесообразно дополнительно учитывать нарушение цикла «сон-бодрствование» как модифицируемый предиктор метаболических нарушений.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: In the context of a sustained increase in the prevalence of obesity and its associated cardiometabolic complications, the importance of identifying additional risk factors is growing, with particular emphasis on sleep disturbances and reduced sleep duration, which contribute to the development and progression of metabolic disorders.</p></sec><sec><title>AIM</title><p>AIM: To assess the severity of disturbances in the sleep–wake cycle in patients with overweight and class I obesity across different categories of risk for disorders of carbohydrate metabolism according to the FINDRISC scale.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: The study included 1,500 Caucasian patients of both sexes, aged 45–70 years, with a BMI ≥25 kg/m². All participants completed questionnaires: FINDRISC (to estimate the risk of developing diabetes mellitus), PSQI (Pittsburgh Sleep Quality Index, last month), and ISI (Insomnia Severity Index).</p></sec><sec><title>RESULTS</title><p>RESULTS: Retrospective analysis showed that 96.6% of patients aged 45–64 years were overweight or had class I obesity. At the second stage of the study, among 782 patients with moderate and high 10‑year risk of type 2 diabetes according to the FINDRISC, sleep disturbances were documented in 696 (89.0 %) individuals.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: In patients with overweight and class I obesity who have a moderate or high 10‑year risk of type 2 diabetes according to the FINDRISC, disturbances of the sleep–wake cycle should be additionally considered as a modifiable predictor of metabolic disorders.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>предиабет</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>шкала FINDRISC</kwd><kwd>десинхроноз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>prediabetes</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>FINDRISC</kwd><kwd>desynchronosis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена по инициативе авторов без привлечения финансирования.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X, Ha S, Lau HC, Yu J. Excess body weight: Novel insights into its roles in obesity comorbidities. Semin Cancer Biol. 2023;92:16–27. doi: https://doi.org/10.1016/j.semcancer.2023.03.008</mixed-citation><mixed-citation xml:lang="en">Zhang X, Ha S, Lau HC, Yu J. Excess body weight: Novel insights into its roles in obesity comorbidities. Semin Cancer Biol. 2023;92:16–27. doi: https://doi.org/10.1016/j.semcancer.2023.03.008</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Каде А.Х., Чабанец Е.А., Занин С.А., и др. Дисфункция жировой ткани (адипозопатия) как основной механизм метаболического синдрома // Вопросы питания. — 2022. — Т. 91. — №1. — С. 27–36. doi: https://doi.org/10.33029/0042-8833-2022-91-1-27-36</mixed-citation><mixed-citation xml:lang="en">Kade AK, Chabanets EA, Zanin SA, et al. Sick fat (adiposopathy) as the main contributor to metabolic syndrome. Voprosy pitaniia. 2022;91(1):27–36. (in Russ.) doi: https://doi.org/10.33029/0042-8833-2022-91-1-27-36</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786. doi: https://doi.org/10.3390/ijms23020786</mixed-citation><mixed-citation xml:lang="en">Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786. doi: https://doi.org/10.3390/ijms23020786</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lim HM, Chia YC, Koay ZL. Performance of the Finnish Diabetes Risk Score (FINDRISC) and Modified Asian FINDRISC (ModAsian FINDRISC) for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in primary care. Prim Care Diabetes. 2020;14(5):494–500. doi: https://doi.org/10.1016/j.pcd.2020.02.008</mixed-citation><mixed-citation xml:lang="en">Lim HM, Chia YC, Koay ZL. Performance of the Finnish Diabetes Risk Score (FINDRISC) and Modified Asian FINDRISC (ModAsian FINDRISC) for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in primary care. Prim Care Diabetes. 2020;14(5):494–500. doi: https://doi.org/10.1016/j.pcd.2020.02.008</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Saaristo T, Peltonen M, Lindström J, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res. 2005;2(2):67–72. doi: https://doi.org/10.3132/dvdr.2005.011</mixed-citation><mixed-citation xml:lang="en">Saaristo T, Peltonen M, Lindström J, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res. 2005;2(2):67–72. doi: https://doi.org/10.3132/dvdr.2005.011</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chaudhry BA, Brian MS, Morrell JS. The Relationship between Sleep Duration and Metabolic Syndrome Severity Scores in Emerging Adults. Nutrients. 2023;15(4):1046. doi: https://doi.org/10.3390/nu15041046</mixed-citation><mixed-citation xml:lang="en">Chaudhry BA, Brian MS, Morrell JS. The Relationship between Sleep Duration and Metabolic Syndrome Severity Scores in Emerging Adults. Nutrients. 2023;15(4):1046. doi: https://doi.org/10.3390/nu15041046</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ai S, Zhang J, Zhao G, et al. Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank. Eur Heart J. 2021;42(34):3349–3357. doi: https://doi.org/10.1093/eurheartj/ehab170</mixed-citation><mixed-citation xml:lang="en">Ai S, Zhang J, Zhao G, et al. Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank. Eur Heart J. 2021;42(34):3349–3357. doi: https://doi.org/10.1093/eurheartj/ehab170</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zimmet P, Alberti KGMM, Stern N, et al. The Circadian Syndrome: is the Metabolic Syndrome and much more!. J Intern Med. 2019;286(2):181–191. doi: https://doi.org/10.1111/joim.12924</mixed-citation><mixed-citation xml:lang="en">Zimmet P, Alberti KGMM, Stern N, et al. The Circadian Syndrome: is the Metabolic Syndrome and much more!. J Intern Med. 2019;286(2):181–191. doi: https://doi.org/10.1111/joim.12924</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Shi Z, Tuomilehto J, Kronfeld-Schor N, et al. The circadian syndrome predicts cardiovascular disease better than metabolic syndrome in Chinese adults. J Intern Med. 2021;289(6):851–860. doi: https://doi.org/10.1111/joim.13204</mixed-citation><mixed-citation xml:lang="en">Shi Z, Tuomilehto J, Kronfeld-Schor N, et al. The circadian syndrome predicts cardiovascular disease better than metabolic syndrome in Chinese adults. J Intern Med. 2021;289(6):851–860. doi: https://doi.org/10.1111/joim.13204</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Остроумова О.Д., Кочетков А.И., Эбзеева Е.Ю., Переверзев А.П. Инсомния и полиморбидность: учебное пособие. — М.: ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; 2021.</mixed-citation><mixed-citation xml:lang="en">Ostroumova OD, Kochetkov AI, Ebzeeva EYu, Pereverzev AP. Insomnia and polymorbidity: a study guide. Moscow: Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; 2021. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601-8. doi: https://doi.org/10.1093/sleep/34.5.601</mixed-citation><mixed-citation xml:lang="en">Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601-8. doi: https://doi.org/10.1093/sleep/34.5.601</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Желябина О.В., Елисеев М.С., Глухова С.И., и др. Факторы риска развития сахарного диабета 2-го типа у пациентов с подагрой: результаты проспективного исследования // Современная ревматология. — 2022. — Т. 16. — №1. — С. 52–59. doi: https://doi.org/10.14412/1996-7012-2022-1-52-59</mixed-citation><mixed-citation xml:lang="en">Zhelyabina OV, Eliseev MS, Glukhova SI, et al. Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study. Sovremennaya Revmatologiya. 2022;16(1):52–59 (In Russ.) doi: https://doi.org/10.14412/1996-7012-2022-1-52-59</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Riise HKR, Graue M, Igland J, et al. Prevalence of increased risk of type 2 diabetes in general practice: a crosssectional study in Norway. BMC Prim Care. 2023;24(1):151. doi: https://doi.org/10.1186/s12875-023-02100-x</mixed-citation><mixed-citation xml:lang="en">Riise HKR, Graue M, Igland J, et al. Prevalence of increased risk of type 2 diabetes in general practice: a crosssectional study in Norway. BMC Prim Care. 2023;24(1):151. doi: https://doi.org/10.1186/s12875-023-02100-x</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Викулова О.К., и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021 // Сахарный диабет. — 2021. — Т. 24. — №3. — С. 204–221. doi: https://doi.org/10.14341/DM12759</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Vikulova OK, et.al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204–221. (In Russ.)] doi: https://doi.org/10.14341/DM12759</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Суплотова Л.А., Бельчикова Л.Н., Рожнова Н.А., Судницына А.С. Эпидемиологические характеристики сахарного диабета 2 типа в Тюменской области за период 2012–2022 гг. // Медицинская наука и образование Урала. — 2023. — Т. 24. — №3. — С. 79–83. doi: https://doi.org/10.36361/18148999_2023_24_3_79</mixed-citation><mixed-citation xml:lang="en">Suplotova LA, Belchikova LN, Rozhnova NA, Sudnitsyna AS. Epidemiological characteristics of diabetes type 2 in Tyumen region for over 10-year period (2012–2022). Medical science and education of Ural. 2023;24(3):79–83. (In Russ.) doi: https://doi.org/10.36361/18148999_2023_24_3_79</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Котова М.Б., Максимов С.А., и др. Приверженность здоровому образу жизни в России по данным исследования ЭССЕ-РФ: есть ли «ковидный след»? // Кардиоваскулярная терапия и профилактика. — 2023. — Т. 22. — №8S. — С. 8–19. doi: https://doi.org/10.15829/1728-8800-2023-3788.</mixed-citation><mixed-citation xml:lang="en">Drapkina ОM, Kotova MB, Maksimov SA, et al. Adherence to a healthy lifestyle in Russia according to the ESSE-RF study: is there a COVID-19 trace? Cardiovascular Therapy and Prevention. 2023;22(8S):8–19. (In Russ.) doi: https://doi.org/10.15829/1728-8800-2023-3788.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Rohm TV, Meier DT, Olefsky JM, et al. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31–55. doi: https://doi.org/10.1016/j.immuni.2021.12.013</mixed-citation><mixed-citation xml:lang="en">Rohm TV, Meier DT, Olefsky JM, et al. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31–55. doi: https://doi.org/10.1016/j.immuni.2021.12.013</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Стрижелецкий В.В., Гомон Ю.М., Спичакова Е.А., и др. Ожирение I степени: исследование реальной клинической практики в Российской Федерации // Медицинские технологии. Оценка и выбор. — 2024. — Т. 46. — №1. — С. 83–90. doi: https://doi.org/10.17116/medtech20244601183</mixed-citation><mixed-citation xml:lang="en">Strizheletskiy VV, Gomon YM, Spichakova EA, et al. Obesity grade I: a study of real clinical practice in the Russian Federation. Medical Technologies. Assessment and Choice. 2024;46(1):83–90. (In Russ.) doi: https://doi.org/10.17116/medtech20244601183</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Dhadse R, Yadav D, Thakur L, et al. Clinical Profile, Risk Factors, and Complications in Young-Onset Type 2 Diabetes Mellitus. Cureus. 2024;16(9):e68497. doi: https://doi.org/10.7759/cureus.68497</mixed-citation><mixed-citation xml:lang="en">Dhadse R, Yadav D, Thakur L, et al. Clinical Profile, Risk Factors, and Complications in Young-Onset Type 2 Diabetes Mellitus. Cureus. 2024;16(9):e68497. doi: https://doi.org/10.7759/cureus.68497</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chasens ER, Imes CC, Kariuki JK, et al. Sleep and Metabolic Syndrome. Nurs Clin North Am. 2021;56(2):203–217. doi: https://doi.org/10.1016/j.cnur.2020.10.012</mixed-citation><mixed-citation xml:lang="en">Chasens ER, Imes CC, Kariuki JK, et al. Sleep and Metabolic Syndrome. Nurs Clin North Am. 2021;56(2):203–217. doi: https://doi.org/10.1016/j.cnur.2020.10.012</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Smiley A, King D, Bidulescu A. The Association between Sleep Duration and Metabolic Syndrome: The NHANES 2013/2014. Nutrients. 2019;11(11):2582. doi: https://doi.org/10.3390/nu11112582</mixed-citation><mixed-citation xml:lang="en">Smiley A, King D, Bidulescu A. The Association between Sleep Duration and Metabolic Syndrome: The NHANES 2013/2014. Nutrients. 2019;11(11):2582. doi: https://doi.org/10.3390/nu11112582</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Che Y, Shimizu Y, Hayashi T, et al. Chronic circadian rhythm disorder induces heart failure with preserved ejection fraction-like phenotype through the Clock-sGC-cGMP-PKG1 signaling pathway. Sci Rep. 2024;14(1):10777. doi: https://doi.org/10.1038/s41598-024-61710-2</mixed-citation><mixed-citation xml:lang="en">Che Y, Shimizu Y, Hayashi T, et al. Chronic circadian rhythm disorder induces heart failure with preserved ejection fraction-like phenotype through the Clock-sGC-cGMP-PKG1 signaling pathway. Sci Rep. 2024;14(1):10777. doi: https://doi.org/10.1038/s41598-024-61710-2</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
